JonathanSSerodyMD
Oncology • Chapel Hill, NCHematologic Oncology
Elizabeth Thomas Professor of Medicine Microbiology and Immunology, University of North Carolina at Chapel Hill School of Medicine; Division Chief of Hematology
Dr. Serody is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
125 Mason Farm Rd
Rm 5012
Chapel Hill, NC 27599Phone+1 919-966-6975Fax+1 919-843-9107- Is this information wrong?
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 1993 - 1993
University of North Carolina HospitalsFellowship, Infectious Disease, 1989 - 1993- University of North Carolina HospitalsResidency, Internal Medicine, 1986 - 1989
University of Virginia School of MedicineClass of 1986
Certifications & Licensure
NC State Medical License 1988 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2006-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Elizabeth Thomas Professor of Medicine University of North Carolina, 2006
Clinical Trials
- Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer Start of enrollment: 2004 Jan 01
- Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer Start of enrollment: 2005 Dec 01
Publications & Presentations
PubMed
- 1 citationsAnti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30lymphoma: a phase 1 study.Natalie S Grover, George Hucks, Marcie L Riches, Anastasia Ivanova, Dominic T Moore, Thomas C Shea, Mary Beth Seegars, Paul M Armistead, Kimberly A Kasow, Anne W Beave...> ;The Lancet. Haematology. 2024 Mar 28
- Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity.Haojie Dong, Xin He, Lei Zhang, Wei Chen, Yi-Chun Lin, Song-Bai Liu, Huafeng Wang, Le Xuan Truong Nguyen, Min Li, Yinghui Zhu, Dandan Zhao, Lucy Ghoda, Jonathan Serody...> ;Nature Cancer. 2024 Feb 27
- 2 citationsFGFR inhibition augments anti-PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppression.Okato, A., Utsumi, T., Ranieri, M., Zheng, X., Zhou, M., Pereira, L., Chen, T., Kita, Y., Wu, D., Hyun, H., Lee, H., Gdowski, A., Raupp, J., Clark-Garvey, S., Manocha,...> ;The Journal of Clinical Investigation. 2024 Jan 16
- Join now to see all
Journal Articles
- Endogenous Retrovirus Expression Is Associated with Response to Immune Checkpoint Blockade in Clear Cell Renal Cell CarcinomaBenjamin G. Vincent, Jonathan S. Serody, Gregory Riedlinger, Shridar Ganesan, The Journal of Clinical Investigation
- Small-Molecule BCL6 Inhibitor Effectively Treats Mice with Non-Sclerodermatous Chronic Graft-Versus-Host DiseaseJoseph H Antin, Bruce Blazar, Leo Luznik, John Koreth, Ivan Maillard, Robert J Soiffer, James E Bradner, Jonathan S Serody, Jerome Ritz, Blood
Abstracts/Posters
- Retrospective Cohort Study Analyzing the Safety and Efficacy of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed/Refractory Hodgkin LymphomaJonathan S Serody, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Third Party Type 2 Innate Lymphoid Cells Treat and Prevent GI Tract Acute GvHDJonathan S Serody, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AMLJonathan S Serody, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Press Mentions
Putting the 'STING' on CAR-T Cells to Turn Them Against Breast Cancer and Other Solid TumorsJanuary 4th, 2021- Excellent Research Results for CAR-T Cell Therapy Against Hodgkin LymphomaJuly 23rd, 2020
ASCO Announces 2020 AwardsApril 24th, 2020- Join now to see all
Grant Support
- Evaluating the Immune Infiltrate in Basal-like and Claudin-low Breast CancerNational Cancer Institute2012–Present
- Targeting Lymphoid Migration for the Prevention/Treatment of GVHDNational Heart Lung and Blood Institute2012–Present
- Evaluating the Interaction of T cells and Macrophages in Cutaneous GVHDNational Cancer Institute2012–Present
- Treg Migration In GVHDNational Institute Of Allergy And Infectious Diseases2011
- Modeling TH17 Cells In Acute GVHDNational Institute Of Allergy And Infectious Diseases2010
- Breast Cancer Vaccine Strategies For Her2-Overexpressing And Lum. B TumorsNational Cancer Institute2006–2010
- Treg Migration In GVHDNational Institute Of Allergy And Infectious Diseases2005–2009
- Clinical Trial: Lccc 0418: Phase I/II Multieptitope Dendritic Cell Vaccine In BNational Center For Research Resources2008
- Lccc 0418: Phase I/II Multieptitope Dendritic Cell Vaccine In Breast CancerNational Center For Research Resources2007
- Lccc 0310 Dendritic Cell Vaccine Given With Trastuzumab And VinorelbineNational Center For Research Resources2005–2007
- Mechanisms Involved In T Cell Trafficking In GVHDNational Cancer Institute2003–2007
- Multimodality Therapy For Metastatic Breast CancerNational Cancer Institute2005–2006
- Enhancing A Breast Cancer VaccineNational Cancer Institute2001–2002
- Immunotherapy For Metastatic Breast CancerNational Cancer Institute2000–2001
- ID Of Epitopes From CML Recognized By T CellsNational Cancer Institute1996–2000
- Cloning And Regulation Of A Lactoferrin Receptor GeneNational Institute Of Allergy And Infectious Diseases1991
Professional Memberships
- Member
- Member
Hospital Affiliations
University of North Carolina HospitalsChapel Hill, North Carolina
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
